Evaluation of the potential for and clinical impact of increased ALT in patients using the AbbVie 2-DAA or 3-DAA Regimens in a real world setting

06/07/2016
02/07/2024
EU PAS number:
EUPAS13832
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

p15421-protocol-pmos-abstract

English (57.75 KB - PDF) View document
Updated protocol

p15421-protocol-pmos FINAL_Redacted

First published: 22/02/2024
English (200.83 KB - PDF) View document
Study results
Study results

p15421-pmos-results-abstract-final-redacted

English (1.62 MB - PDF) View document
Study report
Other information